Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
Clinical and Applied Thrombosis/Hemostasis · 2023
DOI: 10.1177/10760296221129591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Suman Preet Bharath und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, 22494Cedars-Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Intracranial Thrombosis, Venous Thrombosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Cerebral venous thrombosis (CVT) is a life-threatening neurological condition. There is limited evidence for the use of direct oral anticoagulants (DOAC) for long-term anticoagulation in this patient population. We report a case series of patients treated with apixaban and their clinical course.
Methods
This was a retrospective cohort study. Patients diagnosed with CVT in a defined time period at our institution were screened for long-term anticoagulation and patients who were treated with apixaban were included in this study.
Results
A total of nine patients were included in this study. The mean age was 36 years and 56% of the patients included were women. All received initial anticoagulation with unfractionated heparin (UFH) infusion for at least twenty-four hours, except for one patient who had anti-thrombin III deficiency and was treated with argatroban infusion. For long-term anticoagulation, 56% of patients received apixaban 10 mg twice daily for the first five to seven days followed by 5 mg twice daily, while the remaining 44% were transitioned from IV anticoagulation to apixaban 5 mg twice daily. There were no adverse events reported, except for one patient who developed anemia after 7 months of treatment and required a blood transfusion. Complete recanalization was achieved in 78% while 22% had partial recanalization. Follow-up time ranged from six to twenty-three months.
Conclusion
The use of apixaban for long-term anticoagulation in CVT resulted in recanalization in all of the patients in this case series without any major side effects. This case series adds to the emerging studies demonstrating the utility of apixaban for CVT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, 22494Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Division of Neurology, University of Southern California, Los Angeles, CA, USA.
- Division of Pharmacology, 24263Hackensack Meridian Health JFK University Medical Center, Edison, NJ, USA.
- Division of Neurology, 24263Hackensack Meridian Health JFK University Medical Center, Edison, NJ, USA.
ORCID-Profile: Suman Preet Bharath
Zitieren
APA
Bharath, S. P., Arshad, H., Song, Y. B., & Kirmani, J. F. (2023). Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296221129591
Vancouver
Bharath SP, Arshad H, Song YB, Kirmani JF. Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296221129591
BibTeX
@article{Bharath2023,
author = {Bharath, Suman Preet and Arshad, Hasnain and Song, Yong-Bum and Kirmani, Jawad F},
title = {Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2023},
doi = {10.1177/10760296221129591}
}
EUVIMED